28,250 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,250 shares of the company’s stock, valued at approximately $540,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in shares of Syndax Pharmaceuticals by 380.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,400 shares of the company’s stock worth $41,000 after acquiring an additional 1,900 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Syndax Pharmaceuticals by 48.1% during the second quarter. Ameritas Investment Partners Inc. now owns 3,525 shares of the company’s stock worth $61,000 after buying an additional 1,145 shares during the period. Principal Financial Group Inc. purchased a new stake in Syndax Pharmaceuticals during the second quarter worth approximately $187,000. State Board of Administration of Florida Retirement System increased its position in shares of Syndax Pharmaceuticals by 28.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 11,949 shares of the company’s stock worth $205,000 after acquiring an additional 2,637 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its stake in shares of Syndax Pharmaceuticals by 163,112.5% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 13,057 shares of the company’s stock valued at $224,000 after acquiring an additional 13,049 shares during the period.

SNDX has been the subject of several recent research reports. Morgan Stanley increased their price target on Syndax Pharmaceuticals from $20.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, October 12th. Zacks Investment Research downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Buy” and an average price target of $25.00.

In other news, COO Michael A. Metzger sold 44,704 shares of the firm’s stock in a transaction dated Monday, October 25th. The stock was sold at an average price of $19.13, for a total transaction of $855,187.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael A. Metzger sold 1,676 shares of the firm’s stock in a transaction dated Friday, December 17th. The shares were sold at an average price of $19.02, for a total value of $31,877.52. The disclosure for this sale can be found here. Insiders have sold 237,175 shares of company stock valued at $4,726,677 over the last 90 days. Insiders own 7.60% of the company’s stock.

Shares of NASDAQ SNDX opened at $18.09 on Friday. Syndax Pharmaceuticals, Inc. has a 12-month low of $13.02 and a 12-month high of $25.68. The company has a market cap of $893.50 million, a P/E ratio of -9.94 and a beta of 1.57. The company has a current ratio of 8.30, a quick ratio of 8.30 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average price of $18.67 and a 200 day moving average price of $17.73.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, November 15th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.24. The company had revenue of $12.38 million during the quarter. Syndax Pharmaceuticals had a negative return on equity of 41.03% and a negative net margin of 678.57%. During the same quarter in the prior year, the business earned ($0.46) earnings per share. On average, sell-side analysts forecast that Syndax Pharmaceuticals, Inc. will post -2.06 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

See Also: Monthly Dividend Stocks Can Provide Solid Income

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.